Literature DB >> 29158037

Quantitative imaging, dosimetry and metrology; Where do National Metrology Institutes fit in?

A J Fenwick1, J L Wevrett2, K M Ferreira3, A M Denis-Bacelar3, A P Robinson4.   

Abstract

In External Beam Radiotherapy, National Metrology Institutes (NMIs) play a critical role in the delivery of accurate absorbed doses to patients undergoing treatment. In contrast for nuclear medicine the role of the NMI is less clear and although significant work has been done in order to establish links for activity measurement, the calculation of administered absorbed doses is not traceable in the same manner as EBRT. Over recent decades the use of novel radiolabelled pharmaceuticals has increased dramatically. The limitation of secondary complications due to radiation damage to non-target tissue has historically been achieved by the use of activity escalation studies during clinical trials and this in turn has led to a chronic under dosing of the majority of patients. This paper looks to address the difficulties in combining clinical everyday practice with the grand challenges laid out by national metrology institutes to improve measurement capability in all walks of life. In the life sciences it can often be difficult to find the correct balance between pure research and practical solutions to measurement problems, and this paper is a discussion regarding these difficulties and how some NMIs have chosen to tackle these issues. The necessity of establishing strong links to underlying standards in the field of quantitative nuclear medicine imaging is highlighted. The difficulties and successes of current methods for providing traceability in nuclear medicine are discussed. Crown
Copyright © 2017. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29158037     DOI: 10.1016/j.apradiso.2017.11.014

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN: 0969-8043            Impact factor:   1.513


  4 in total

Review 1.  Imaging and dosimetry for alpha-particle emitter radiopharmaceutical therapy: improving radiopharmaceutical therapy by looking into the black box.

Authors:  George Sgouros; Eric Frey; Yong Du; Rob Hobbs; Wesley Bolch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-11-16       Impact factor: 9.236

2.  Bone lesion absorbed dose profiles in patients with metastatic prostate cancer treated with molecular radiotherapy.

Authors:  Ana M Denis-Bacelar; Sarah J Chittenden; V Ralph McCready; Antigoni Divoli; David P Dearnaley; Joe M O'Sullivan; Bernadette Johnson; Glenn D Flux
Journal:  Br J Radiol       Date:  2018-02-05       Impact factor: 3.039

3.  Recommendations for Multicentre Clinical Trials Involving Dosimetry for Molecular Radiotherapy.

Authors:  J Taprogge; J Wadsley; E Miles; G D Flux
Journal:  Clin Oncol (R Coll Radiol)       Date:  2020-12-18       Impact factor: 4.126

4.  Cherenkov light emission in molecular radiation therapy of the thyroid and its application to dosimetry.

Authors:  Jigar Dubal; Pedro Arce; Christopher South; Lucia Florescu
Journal:  Biomed Opt Express       Date:  2022-03-23       Impact factor: 3.562

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.